PMID- 24276087
OWN - NLM
STAT- MEDLINE
DCOM- 20140730
LR  - 20151119
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 26
IP  - 1
DP  - 2014 Jan
TI  - Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis.
PG  - 1-6
LID - 10.1097/BOR.0000000000000005 [doi]
AB  - PURPOSE OF REVIEW: The current standard therapy for antineutrophil cytoplasm 
      antibody-associated vasculitis (AAV), high-dose glucocorticoid and 
      cyclophosphamide followed by azathioprine, has improved the disease prognosis. 
      However, there are still unmet needs. For example, reducing relapse risk and 
      glucocorticoid toxicity. Newer therapies are needed. RECENT FINDINGS: Potential 
      newer drugs are emerging following a better understanding of disease mechanisms 
      and the availability of targeted therapies to B cells, T cells, proinflammatory 
      cytokines and complement. Rituximab, an anti-CD20 monoclonal antibody, has proven 
      efficacy in remission induction therapy for AAV, and two trials with rituximab as 
      remission maintenance therapy are ongoing. Clinical trials evaluating 
      mycophenolate mofetil as remission induction therapy, gusperimus, belimumab and 
      complement factor C5a inhibition are also ongoing, and many other potential 
      candidates are being investigated both clinically and experimentally. SUMMARY: 
      B-cell therapy is now an established treatment in AAV and several other therapies 
      are under evaluation. However, the unmet need in vasculitis therapy remains large 
      and newer therapies either alone or in combination will need to both improve 
      efficacy and permit reductions in glucocorticoid and immunosuppressive exposure.
FAU - Furuta, Shunsuke
AU  - Furuta S
AD  - Lupus and Vasculitis Clinic, Addenbrooke's Hospital, Cambridge University 
      Hospitals, Cambridge, UK.
FAU - Jayne, David
AU  - Jayne D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Complement Inactivating Agents)
RN  - 0 (Cytokines)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug 
      therapy/immunology
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - B-Lymphocytes/drug effects/immunology
MH  - Complement Inactivating Agents/therapeutic use
MH  - Cytokines/antagonists & inhibitors
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Lymphocyte Depletion/methods
MH  - Rituximab
MH  - T-Lymphocytes/drug effects/immunology
EDAT- 2013/11/28 06:00
MHDA- 2014/07/31 06:00
CRDT- 2013/11/27 06:00
PHST- 2013/11/27 06:00 [entrez]
PHST- 2013/11/28 06:00 [pubmed]
PHST- 2014/07/31 06:00 [medline]
AID - 10.1097/BOR.0000000000000005 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2014 Jan;26(1):1-6. doi: 10.1097/BOR.0000000000000005.